Evaluation of Available Cognitive Tools Used to Measure Mild Cognitive Decline: A Scoping Review

Chian Thong Chun1, Kirsty Seward1,2, Amanda Patterson1,2

  • 1School of Health Sciences, Faculty of Health and Medicine, University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.

Nutrients
|November 27, 2021
PubMed

Insights

Identifying early cognitive decline is crucial. This review identifies the most effective cognitive tools, like the MoCA and MMSE, for detecting mild cognitive impairment (MCI) and potentially delaying dementia progression.

Area of Science:

  • Neurology
  • Gerontology
  • Psychometrics

Background:

  • Cognitive decline spans age-associated changes to dementia.
  • Mild cognitive impairment (MCI) represents an intermediate stage.
  • Early interventions may slow pathological progression.

Purpose of the Study:

  • To identify the most effective cognitive tools for early detection of mild cognitive impairment (MCI).
  • To evaluate cognitive tools based on psychometric properties, administration time, and delivery method.

Main Methods:

  • Systematic literature search across five databases.
  • Identification and assessment of 52 distinct cognitive tools.
  • Evaluation of tools based on psychometric properties, administration time, and delivery method.

Main Results:

  • Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), and Clock Drawing Test (CDT) were most cited.
  • Six-item Cognitive Impairment Test (6CIT), MoCA, MMSE, and Hong Kong Brief Cognitive Test (HKBC) showed preferable all-round performance.
  • SAGE and a 4-point CDT were recommended for specific settings.

Conclusions:

  • Several cognitive tools demonstrate effectiveness in screening for MCI.
  • Age and education levels can influence tool performance.
  • Careful selection of cut-off points is necessary for diverse populations.

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
232
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
364
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
735